AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the publication of a report arising from a series of rhinology procedures successfully performed using sufentanil...
Investing.com – U.S. stocks were higher after the close on Thursday, as gains in the Oil & Gas, Technology and Consumer Goods sectors led shares higher. At the close in NYSE, the...
A heavy earnings week is always a busy time for the markets, but is “busy” really the word to describe the past week?First, Let’s Talk About TwitterWell, the...
At fourth-quarter 2019 earnings conference, we expect investors to focus on AcelRx Pharmaceuticals, Inc.’s (NASDAQ:ACRX) updates related to the sales performance of its...
Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced that it has completed enrollment in the phase III study evaluating its lead candidate Diazoxide Choline Controlled-Release...
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.
|Moving Averages||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Technical Indicators||Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Sell||Strong Sell|